Business Context and Reporting Period
This Form 8-K was filed by BioZone Pharmaceuticals, Inc. (noted as Cocrystal Pharma, Inc. in metadata) on August 26, 2013. The report details a private placement transaction involving the sale of debt and equity securities to an accredited investor.
Key Financial Metrics and Transaction Details
- Gross Proceeds: $2,000,000 raised from the sale of a 10% secured convertible promissory note.
- Debt Instrument: $2,000,000 principal amount, 10% annual interest rate, due one year from issuance.
- Conversion Terms: Note convertible at an initial price of $0.20 per share.
- Warrant Terms: Warrant to purchase 10,000,000 shares at an exercise price of $0.40 per share; exercisable immediately and expires in ten years.
- Use of Proceeds: Repayment of outstanding promissory notes to a former executive vice president and general working capital.
- Collateral: The note is secured by a perfected security interest in all tangible and intangible assets of the company, pari passu with previous secured creditors but subordinated to accounts receivable lenders and a specific prior investor.
Material Changes and Unusual Items
The filing reports a material change in the company's capital structure through the issuance of unregistered securities. The transaction includes a "piggy-back" registration right for the buyer for a period of 12 months. A beneficial ownership limitation restricts conversion or exercise if the buyer would own more than 4.99% of the outstanding common stock.
Guidance, Risks, and Contingencies
- Events of Default: The note includes specific events of default, including failure to pay accrued interest, failure to perform obligations, or material inaccuracies in representations, which could trigger immediate repayment of all amounts due.
- Subordination: The new security interest is subordinated to the company's accounts receivable lender and a specific prior investor.
- Regulatory Status: Securities were sold under Section 4(2) and Regulation D (Rule 506) exemptions.
Investor Verification Checklist
- Verify the exact identity of the "Buyer" and their relationship to the company.
- Confirm the total outstanding debt load post-transaction, including the subordinated accounts receivable lender.
- Review the "Events of Default" clauses in the attached Security Agreement (Exhibit 10.4) for potential liquidity triggers.
- Assess the dilution impact of the 10,000,000 warrant shares and the potential conversion of the $2,000,000 note at $0.20 per share.
- Check subsequent filings for any default events or prepayments made on the note.